Definium Therapeutics (DFTX) Common Equity (2020 - 2026)

Definium Therapeutics (DFTX) has 7 years of Common Equity data on file, last reported at $278.8 million in Q1 2026.

• On a quarterly basis, Common Equity rose 25.15% year-over-year to $278.8 million in Q1 2026; TTM through Mar 2026 was $278.8 million, a 25.15% increase from a year earlier, with the FY2025 full-year figure at $332.3 million, up 37.64% from the prior year.
• Common Equity for Q1 2026 stood at $278.8 million, down from $332.3 million in the prior quarter.
• Over the last five years, Common Equity for DFTX reached as high as $332.3 million in Q4 2025 and fell as low as $78.1 million in Q4 2023.
• Historically, Common Equity has averaged $178.1 million across 5 years, with a median of $153.6 million in 2022.
• Across the five-year window, Common Equity soared 209.02% in 2024 and tumbled 50.19% in 2025, its largest moves.
• Year by year, Common Equity stood at $150.9 million in 2022, then slumped by 48.23% to $78.1 million in 2023, then surged by 209.02% to $241.4 million in 2024, then soared by 37.64% to $332.3 million in 2025, then fell by 16.09% to $278.8 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $278.8 million in Q1 2026, $332.3 million in Q4 2025, and $130.6 million in Q3 2025.